NIH and the Drug Discovery Pipeline
A recent article in Newsweek by Sharon Begley and Mary
Carmichael calls attention to the decline over recent years in the number of new drugs
introduced into medical practice. They suggest that NIH funding priorities
should be targeted more directly towards the support of the pre-clinical and
clinical studies required for the introduction of promising drug candidates
into the clinic, arguing that the return on investment in NIH has been
‘approximately as satisfying’ for taxpayers and patients as the return on
public investment in the AIG bailout.
Read more